By a News Reporter-Staff News Editor at Diabetes Week -- Investigators publish new report on Diabetes. According to news originating from Hummelstown, Pennsylvania, by NewsRx correspondents, research stated, "Nanoliposomal technology is a promising drug delivery system that could be employed to improve the pharmacokinetic properties of clearance and distribution in ocular drug delivery to the retina. We developed a nanoscale version of an anionic, cholesterol-fusing liposome that can encapsulate therapeutic levels of minocycline capable of drug delivery."
Our news journalists obtained a quote from the research from the Pennsylvania State University College of Medicine, "We demonstrate that size extrusion followed by size-exclusion chromatography can form a stable 80-nm liposome that encapsulates minocycline at a concentration of 450 ± 30 ?M, which is 2% to 3% of loading material. More importantly, these nontoxic nanoliposomes can then deliver 40% of encapsulated minocycline to the retina after a subconjunctival injection in the STZ model of diabetes. Efficacy of therapeutic drug delivery was assessed via transcriptomic and proteomic biomarker panels. For both the free minocycline and encapsulated minocycline treatments, proinflammatory markers of diabetes were downregulated at both the messenger RNA and protein levels, validating the utility of biomarker panels for the assessment of ocular drug delivery vehicles. Authors developed a nano-liposome that can encapsulate minocycline for optimized intraocular drug delivery."
According to the news editors, the research concluded: "These nontoxic nanoliposomes delivered 40% of encapsulated minocycline to the retina after a subconjunctival injection in a diabetes model."
For more information on this research see: Nanoliposomal minocycline for ocular drug delivery. Nanomedicine, 2013;9(1):130-40. (Elsevier - www.elsevier.com; Nanomedicine - www.elsevier.com/wps/product/cws_home/703416)
The news correspondents report that additional information may be obtained from J.M. Kaiser, Dept. of Pharmacology, Pennsylvania State College of Medicine, Hummelstown, PA 17036, United States. Additional authors for this research include H. Imai, J.K. Haakenson, R.M. Brucklacher, T.E. Fox, S.S. Shanmugavelandy, K.A. Unrath, M.M. Pedersen, P. Dai, W.M. Freeman, S.K. Bronson, T.W. Gardner and M. Kester (see also Diabetes).
Keywords for this news article include: Therapy, Diabetes, Hummelstown, Minocycline, Pennsylvania, United States, Tetracyclines, Drug Delivery Systems, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC